Helicobacter pylori and gastric cancer: current status of the Austrain-Czech-German gastric cancer prevention trial (PRISMA-Study)

Table 1 Current status of the PRISMA study (initiation April 1998)

Endoscopy-histologically screened men between 55 and 65 years of age	Cases (n = 1526)	%
Presence of histological inclusion criteria	n = 279	18.3
Patients randomized	n = 167	58.8a
Non-randomized patients continuing follow-up	n = 109	39.1a
Patients with study endpoints	3	1.8b
Cumulative follow-up (months/years)	3046/253.8

^aPercentage of those who meet all inclusion criteria

^bPercentage of all randomized patients.

Table 2 Currently conducted H. pylori-gastric cancer intervention trials with cancer endpoints

Name	Country	Target group	Age group	Sample size	Main endpoints
SCISC	China	Population	30-65	2400	Gastric cancer
NCI	China	Population	35-69	3400	Gastric cancer , dysplasia
JITHP	Japan	Population	20-59	5000	Gastric cancer
BUPA	U.K.	Population	35-69	56000	Gastric cancer
PRISMA Germany		Male subjects	55-65	3000	Gastric cancer
	Austria	with			dysplasia,adenoma
	Tchech	Corpus
	Republic	dominant
		gastritis